Sunitinib Malate and Multiple Receptor Tyrosine Kinases Inhibitors: Are They Also Novel Drugs for Chronic and Neurophatic Pain?
- 1 July 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (19) , 2858-2859
- https://doi.org/10.1200/jco.2007.11.7358
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signalingMolecular Cancer Therapeutics, 2006
- Expression of nerve growth factor receptors is correlated with progression and prognosis of human pancreatic cancerJournal of Gastroenterology and Hepatology, 2006
- Novel class of pain drugs based on antagonism of NGFTrends in Pharmacological Sciences, 2006
- Cyclin-dependent kinase 5 activity regulates pain signalingProceedings of the National Academy of Sciences, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Tyrosine kinase inhibitors in cancer therapyClinical Biochemistry, 2004
- Acute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor k252aThe Journal of Pain, 2003
- Trk Receptors: Roles in Neuronal Signal TransductionAnnual Review of Biochemistry, 2003